Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Pediatric Endocrinology

Growing Up with TDH: Long-Term Success and Care

At a Glance

Long-term success for children with thyroid dyshormonogenesis (TDH) relies on consistent, daily levothyroxine and regular blood test monitoring. Proper treatment ensures normal brain development, physical growth, and prevents complications like goiters.

Managing thyroid dyshormonogenesis (TDH) is a marathon, not a sprint. While the initial diagnosis is a shock, the long-term reality for most families is a manageable routine that allows children to lead full, normal, and healthy lives [1][2].

The Growth-Based Monitoring Schedule

Because thyroid hormone is the “engine” for growth, your child’s dose must be adjusted frequently as they get bigger. A typical monitoring schedule for blood tests (TSH and fT4) includes:

  • Birth to 6 months: Every 1 to 2 months [3][4].
  • 6 months to 3 years: Every 3 months [3].
  • After age 3: Every 6 to 12 months, or more frequently during growth spurts or puberty [3].

Staying on top of these appointments ensures that your child’s hormone levels remain in the “sweet spot” for brain development and physical height [5][2].

The Importance of Daily Adherence

Consistency is the most powerful tool you have. Levothyroxine actually has a long biological half-life, meaning it builds up and stays in the body for days. However, a daily dose of levothyroxine (LT4) is required to maintain the perfectly steady hormone levels that the developing brain requires [6].

  • Brain Development: The brain continues to develop rapidly until at least age 3. Missing doses during this window can lead to subtle but permanent impacts on IQ and motor skills [6][1].
  • Physical Growth: Thyroid hormone is essential for bone growth. Children who are consistently treated reach their full height potential [1][7].

Preventing Complications

In TDH, the thyroid gland is present and ready to work, but it lacks a specific tool. If the body doesn’t get enough hormone from the medication, the pituitary gland will send a constant “work harder” signal (TSH) [8].

  • Goiter Regrowth: Chronic under-treatment (where TSH remains high) can cause a goiter—an enlarged thyroid—to grow or return [9][8].
  • Long-Term Health: While very rare, decades of unmanaged TSH overstimulation of the thyroid tissue can increase the risk of thyroid nodules or even thyroid carcinoma later in life [10][8]. Fortunately, this is entirely preventable by maintaining normal thyroid levels through consistent medication and regular check-ups [8][3].

Permanent vs. Transient: The “Trial Off”

Around age 3, when the most critical period of brain development is complete, your pediatric endocrinologist may suggest a “trial off” medication [11][12]. This trial is done under very close medical supervision. Because the critical window for initial brain development has passed, the brain is protected during this short testing period.

  • Transient CH: Some children, particularly those with mutations in the DUOX2 or DUOXA2 genes, may find that their thyroid has “matured” and can now function on its own [13][14][15].
  • Permanent CH: If the thyroid levels drop when medication is stopped, it confirms the condition is permanent. While this means lifelong medication, it does not change your child’s potential for a bright and successful future [16][1].

With early detection, modern treatment, and your dedicated care, TDH is a condition that your child will live with—not be limited by.

Common questions in this guide

What is the blood test monitoring schedule for a child with TDH?
For the first six months, blood tests are typically done every 1 to 2 months. Between 6 months and 3 years, they occur every 3 months, and after age 3, they are usually spaced to every 6 to 12 months or during growth spurts.
Why is daily levothyroxine so important for my child's development?
Daily levothyroxine maintains steady thyroid hormone levels essential for proper brain development and physical growth. Missing doses, especially before age 3, can permanently impact a child's cognitive and motor skills.
What happens if my child doesn't get enough thyroid medication?
Chronic under-treatment causes the pituitary gland to release high levels of TSH. This constant overstimulation can lead to the regrowth of a goiter, which is an enlarged thyroid, and may increase the long-term risk of thyroid nodules.
What is the 'trial off' medication at age 3?
Around age 3, a pediatric endocrinologist may temporarily stop the medication under close supervision to see if the child's thyroid can function on its own. This trial helps determine if the condition is permanent or transient.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our specific follow-up schedule for blood tests over the next three years?
  2. 2.Based on my child's genetic mutation (like DUOX2), how likely is it that we can try a 'trial off' medication at age 3?
  3. 3.Are my child's current thyroid levels in the upper half of the normal range, as recommended for brain development?
  4. 4.If my child has a growth spurt or starts school, how will that change our monitoring or dosing?
  5. 5.What should I do if my child resists taking their daily pill as they get older?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Clinical Insight into Congenital Hypothyroidism Among Children.

    Korkmaz HA

    Children (Basel, Switzerland) 2025; (12(1)) doi:10.3390/children12010055.

    PMID: 39857886
  2. 2

    Neurodevelopmental Disorders, Cognitive Function, and Quality of Life in Children with Congenital Hypothyroidism in a Portuguese Population

    Leite-Almeida L, Curval R, Pais-Cunha I, et al.

    Journal of clinical research in pediatric endocrinology 2025; (17(4)):449-457 doi:10.4274/jcrpe.galenos.2025.2024-11-17.

    PMID: 40235218
  3. 3

    Congenital Hypothyroidism: A 2020-2021 Consensus Guidelines Update-An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology.

    van Trotsenburg P, Stoupa A, Léger J, et al.

    Thyroid : official journal of the American Thyroid Association 2021; (31(3)):387-419 doi:10.1089/thy.2020.0333.

    PMID: 33272083
  4. 4

    Newborn Screening Guidelines for Congenital Hypothyroidism in India: Recommendations of the Indian Society for Pediatric and Adolescent Endocrinology (ISPAE) - Part I: Screening and Confirmation of Diagnosis.

    Desai MP, Sharma R, Riaz I, et al.

    Indian journal of pediatrics 2018; (85(6)):440-447 doi:10.1007/s12098-017-2575-y.

    PMID: 29380252
  5. 5

    Congenital Hypothyroidism: Screening and Management.

    Rose SR, Wassner AJ, Wintergerst KA, et al.

    Pediatrics 2023; (151(1)) doi:10.1542/peds.2022-060420.

    PMID: 36827521
  6. 6

    Evaluation and management of the child with hypothyroidism.

    Leung AKC, Leung AAC

    World journal of pediatrics : WJP 2019; (15(2)):124-134 doi:10.1007/s12519-019-00230-w.

    PMID: 30734891
  7. 7

    Assessment of Neurodevelopment and Growth in Congenital Hypothyroidism: Serial 6-Year Follow-up Study of 408 Patients.

    Ha EK, Kim JH, Cha HR, et al.

    The Journal of clinical endocrinology and metabolism 2023; (108(12)):e1588-e1596 doi:10.1210/clinem/dgad364.

    PMID: 37335967
  8. 8

    A Novel Mutation in Thyroid Peroxidase Gene Causing Congenital Goitrous Hypothyroidism in a German-Thai Patient.

    Sriphrapradang C, Thewjitcharoen Y, Chanprasertyothin S, et al.

    Journal of clinical research in pediatric endocrinology 2016; (8(2)):241-5 doi:10.4274/jcrpe.2503.

    PMID: 26761947
  9. 9

    A Large Thyroid Goiter in a Newborn With Congenital Hypothyroidism: Timeline for Decrease in Size of Thyroid.

    July O'Brien K, Ceremsak JJ, Gallant JN, et al.

    Ear, nose, & throat journal 2025; (104(2_suppl)):236S-240S doi:10.1177/01455613231189116.

    PMID: 37501386
  10. 10

    Targeted Next-Generation Sequencing Analysis of a Pendred Syndrome-Associated Thyroid Carcinoma.

    Tong GX, Chang Q, Hamele-Bena D, et al.

    Endocrine pathology 2016; (27(1)):70-5 doi:10.1007/s12022-015-9413-4.

    PMID: 26744121
  11. 11

    Evaluation of patients diagnosed with congenital hypothyroidism by newborn screening between 2011-2019 in Diyarbakir, Turkey.

    Toktaş İ, Erdem Ö, Saribaş S, Özbek MN

    Medicine 2023; (102(51)):e36778 doi:10.1097/MD.0000000000036778.

    PMID: 38134076
  12. 12

    Early Discrimination between Transient and Permanent Congenital Hypothyroidism in Children with Eutopic Gland.

    Messina MF, Aversa T, Salzano G, et al.

    Hormone research in paediatrics 2015; (84(3)):159-64 doi:10.1159/000435811.

    PMID: 26160341
  13. 13

    Molecular and clinical characteristics of pediatric patients with primary congenital hypothyroidism: novel genetic variants and the genotype-phenotype association.

    Zhang CC, Zhang WT, Chen LH, et al.

    Clinica chimica acta; international journal of clinical chemistry 2025; (576()):120426 doi:10.1016/j.cca.2025.120426.

    PMID: 40516894
  14. 14

    Genotype and phenotype correlation in a cohort of Chinese congenital hypothyroidism patients with DUOX2 mutations.

    Zheng Z, Yang L, Sun C, et al.

    Annals of translational medicine 2020; (8(24)):1649 doi:10.21037/atm-20-7165.

    PMID: 33490161
  15. 15

    Molecular and Clinical Features of Congenital Hypothyroidism Due to Multiple DUOX2 Variants.

    Uehara E, Abe K, Tanase-Nakao K, et al.

    Thyroid : official journal of the American Thyroid Association 2024; (34(7)):827-836 doi:10.1089/thy.2024.0046.

    PMID: 38757580
  16. 16

    Quality of life and socioeconomic and educational status in patients with congenital hypothyroidism.

    Danner E, Sund R, Sintonen H, et al.

    Pediatric research 2024; (96(2)):502-509 doi:10.1038/s41390-024-03170-y.

    PMID: 38565918

This page provides educational information about managing pediatric thyroid dyshormonogenesis. It does not replace professional medical advice. Always consult your pediatric endocrinologist regarding your child's specific treatment and monitoring schedule.

Get notified when new evidence is published on Familial thyroid dyshormonogenesis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.